Three independent discounted-cash-flow-style models value Caris Life Sciences, Inc. Common Stock every trading day. 0 of 3 currently price CAI above its market price.
| Free Cash Flow model | $-12.47 |
| Excess Profit model | $7.69 |
| Residual Earnings model | $-0.10 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +3.7% |
| Net debt / EBITDA | 8.4× |
| Gross margin | +66.4% |
| Revenue CAGR | +23.4% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -853.0% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open CAI in StockKitty